9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $405000 | -$10M | 0.0% | -2456.8% | -$9M | — | $6M |
| 2024 | $674000 | -$8M | 0.0% | -1206.2% | -$8M | — | $5M |
| 2023 | $743000 | -$8M | 0.0% | -1103.0% | -$8M | — | $4M |
| 2022 | $810000 | -$10M | 0.0% | -1246.4% | -$11M | — | $3M |
| 2021 | $853000 | -$13M | 0.0% | -1505.5% | -$10M | — | $4M |
| 2020 | $763000 | -$14M | 0.0% | -1853.1% | -$12M | — | $8M |
| 2019 | $2M | -$13M | 0.0% | -590.9% | -$11M | — | $3M |
| 2018 | $4M | -$7M | 0.0% | -141.7% | -$4M | — | $4M |
| 2017 | $789000 | -$5M | 0.0% | -910.6% | -$9M | — | $4M |
How the market has priced CANF against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Can-Fite BioPharma Ltd.'s revenue has declined 11.9% per year. These are computed facts, not advice.
As of FY2025, Can-Fite BioPharma Ltd. reported — of total debt against $6M of cash; operating income covered interest expense -35.0×.
In FY2025, gross margin was —, operating margin -2456.8%, and net margin -2426.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.